信邦制药(002390) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥1,566,731,553.02, representing a year-on-year increase of 1.56%[4] - The net profit attributable to shareholders was ¥90,553,551.86, a decrease of 17.33% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥91,966,043.75, an increase of 15.82% year-on-year[4] - Total operating revenue for Q3 2023 reached CNY 4,823,207,646.87, an increase from CNY 4,686,217,833.13 in the same period last year, representing a growth of approximately 2.9%[19] - Net profit for Q3 2023 was CNY 303,445,405.77, up from CNY 276,722,271.76 in Q3 2022, reflecting an increase of approximately 9.6%[20] - Total comprehensive income for the period reached ¥303,445,405.77, an increase from ¥276,722,271.76 in the previous period, representing a growth of approximately 9.3%[21] - Net profit attributable to the parent company was ¥246,574,999.15, up from ¥241,031,448.38, indicating a slight increase of about 2.3%[21] Cash Flow - The cash flow from operating activities for the year-to-date was ¥728,135,122.51, reflecting a significant increase of 36.85%[8] - Cash flow from operating activities generated a net amount of ¥728,135,122.51, significantly higher than ¥532,062,786.18 in the prior period, marking an increase of approximately 37%[44] - Cash inflow from operating activities totaled ¥5,166,858,055.46, compared to ¥5,060,748,746.78, showing a growth of about 2.1%[44] - Cash outflow from operating activities was ¥4,438,722,932.95, down from ¥4,528,685,960.60, indicating a decrease of approximately 2%[44] - Cash flow from investing activities resulted in a net outflow of ¥44,793,241.06, an improvement from a net outflow of ¥77,355,165.38 in the previous period[45] - Cash flow from financing activities showed a net outflow of ¥500,578,443.93, compared to a net inflow of ¥186,244,247.19 in the prior period, indicating a significant change in financing strategy[45] - The company reported a total cash inflow from financing activities of ¥1,170,630,222.41, down from ¥1,627,019,026.65, indicating a reduction of about 28%[45] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,627,215,378.06, a decrease of 1.69% from the end of the previous year[4] - The total assets of the company as of September 30, 2023, were CNY 9,627,215,378.06, down from CNY 9,793,091,573.35 at the beginning of the year, a decrease of about 1.7%[16] - The company reported a decrease in accounts receivable to CNY 2,869,048,191.76 from CNY 2,912,823,639.68, a decline of approximately 1.5%[14] - The company's total liabilities decreased to CNY 5,781,007,199.89 from CNY 5,806,180,998.23, reflecting a reduction of about 0.4%[14] - Total liabilities decreased from CNY 2,728,042,922.48 to CNY 2,481,464,177.48, a reduction of approximately 9.06%[47] - Total equity increased from CNY 7,065,048,650.87 to CNY 7,145,751,200.58, reflecting a growth of about 1.14%[48] Research and Development - Research and development expenses increased by 354.16% year-on-year, amounting to ¥2,047,197.90[7] - Research and development expenses for Q3 2023 were CNY 2,047,197.90, significantly higher than CNY 450,762.86 in Q3 2022, indicating an increase of approximately 353.5%[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 75,495[8] - The company repurchased a total of 16,019,740 shares, representing 0.82% of the total share capital, with a maximum transaction price of CNY 4.70 per share[58] - The company plans to use self-owned funds to repurchase shares for employee stock ownership plans, with a total repurchase amount between CNY 100 million and CNY 200 million[58] Other Financial Metrics - The weighted average return on equity was 1.32%, down by 0.31 percentage points compared to the previous year[4] - The company’s investment income for Q3 2023 was a loss of CNY 788,943.67, compared to a gain of CNY 37,426,822.02 in Q3 2022[20] - The company's earnings per share (EPS) attributable to shareholders was CNY 0.2466 for Q3 2023, compared to CNY 0.2410 for the same period last year, indicating a slight increase of about 2.3%[20] - Basic and diluted earnings per share both stood at ¥0.1270, compared to ¥0.1240 in the previous period, reflecting an increase of 2.4%[21] Government Subsidies - The company received government subsidies amounting to ¥900,717.99 during the reporting period[6] Accounting Standards - The company has adopted new accounting standards starting in 2023, impacting the financial reporting structure[54]